We investigated in cerebral penetrating arterioles the signaling mechanisms and dose-dependency of extracellular magnesium-induced vasodilation and also its vasodilatory effects in vessels preconstricted with agonists associated with delayed cerebral vasospasm following SAH. Male rat penetrating arterioles were cannulated. Their internal diameters were monitored. To investigate mechanisms of magnesiuminduced vasodilation, inhibitors of endothelial function, potassium channels and endothelial impairment were tested. To simulate cerebral vasospasm we applied several spasmogenic agonists. Increased extracellular magnesium concentration produced concentration-dependent vasodilation, which was partially attenuated by non-specific calcium-sensitive potassium channel inhibitor tetraethylammonium, but not by other potassium channel inhibitors. Neither the nitric oxide synthase inhibitor L-NNA nor endothelial impairment induced by air embolism reduced the dilation. Although the magnesium-induced vasodilation was slightly attenuated by the spasmogen ET-1, neither application of PF 2␣ nor TXA 2 analog effect the vasodilation. Magnesium induced a concentration-and smooth muscle cell-dependent dilation in cerebral penetrating arterioles. Calcium-sensitive potassium channels of smooth muscle cells may play a key role in magnesium-induced vasodilation. Magnesium also dilated endothelium-impaired vessels as well as vessels preconstricted with spasmogenic agonists. These results provide a fundamental background for the clinical use of magnesium, especially in treatment against delayed cerebral ischemia or vasospasm following SAH.
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Introduction
Development of delayed cerebral ischemia (DCI) following subarachnoid hemorrhage (SAH), which results in an unfavorable clinical outcome, is thought to be caused by the combined effects of delayed cerebral vasospasm, arteriolar constriction and microthrombosis, cortical spreading ischemia, and processes triggered by early brain injury (Macdonald, 2014) . Delayed cerebral vasospasm is one of the major causes of DCI, however, its pathophysiological mechanisms still remain unresolved despite progress in experimental and human investigations, thus limiting the number of available effective therapies. Magnesium is a * Corresponding author at: Department of Neurosurgery, Shinshu University 
